<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136338">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326481</url>
  </required_header>
  <id_info>
    <org_study_id>105BC102</org_study_id>
    <nct_id>NCT01326481</nct_id>
  </id_info>
  <brief_title>Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer</brief_title>
  <acronym>TRC105</acronym>
  <official_title>An Open Label Phase 1B Dose-Finding Study of TRC105 in Combination With Capecitabine for Progressive or Recurrent Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tracon Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Tracon Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the recommended phase 2 dose and overall safety
      and tolerability of TRC105 when given in combination with capecitabine for the treatment of
      patients with progressive or recurrent metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Maximum Tolerated Dose of TRC105 in Combination with Capecitabine</measure>
    <time_frame>1.5 years</time_frame>
    <description>Assess safety and dose limiting toxicity by dose cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TRC105 pharmacokinetic concentrations</measure>
    <time_frame>1.5 years</time_frame>
    <description>Peak and trough concentrations will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response to TRC105</measure>
    <time_frame>1.5 years</time_frame>
    <description>Serial blood samples will be tested for immune response to TRC105.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response according to RECIST 1.1</measure>
    <time_frame>1.5 years</time_frame>
    <description>The best response according to RECIST 1.1 for each patient with measurable disease who received at least one dose of study drug will be listed by cohort and tumor type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic biomarker sample analysis</measure>
    <time_frame>1.5 years</time_frame>
    <description>Serial blood samples will be tested for change in angiogenic biomarkers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC105</intervention_name>
    <description>IV</description>
    <arm_group_label>Single</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven advanced solid cancer for which curative therapy is not
             available (Part 1 only)

          -  Histologically proven metastatic Her-2-negative breast cancer (Part 2 only)

          -  Measurable disease by RECIST 1.1 criteria (Part 2 only)

          -  Willing and able to consent for self to participate in study

          -  Progressive or recurrent disease after prior systemic chemotherapy regimen

          -  Age ≥ 18 years

          -  ECOG performance status of 0 or 1

          -  Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade ≤ 1 or
             baseline (except alopecia)

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior treatment with more than one systemic chemotherapy regimen for metastatic
             disease.

          -  Prior treatment with TRC105

          -  History of hypersensitivity reaction to antimetabolite therapy

          -  Receipt of an investigational agent within 28 days of starting study treatment

          -  Prior surgery (including open biopsy), radiation therapy or systemic therapy within
             28 days of starting study treatment

          -  Minor surgical procedures within 14 days prior to first dose of TRC105

          -  History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or
             new evidence of brain or leptomeningeal disease

          -  Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient
             ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the
             past 6 months

          -  Uncontrolled chronic hypertension defined as systolic &gt; 140 or diastolic &gt; 90 despite
             optimal therapy

          -  Past medical history of acquired or inherited coagulopathy including patients with
             known hereditary hemorrhagic telangiectasia

          -  Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days
             prior to first dose with TRC105

          -  Cardiac dysrhythmias of NCI CTCAE Grade ≥ 2 within the last month

          -  Hemorrhage within 28 days of starting study treatment

          -  Unhealed wounds within 28 days of starting study treatment

          -  History of peptic ulcer disease or gastritis within the past 6 months, unless treated
             for the condition and complete resolution has been documented by
             esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment

          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
             related illness

          -  Known active viral or nonviral hepatitis

          -  History of hypersensitivity reaction to human or mouse antibody products

          -  Lung cancer with central chest lesions

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>August 27, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRC105</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>CD105</keyword>
  <keyword>Endoglin</keyword>
  <keyword>TRACON Pharma</keyword>
  <keyword>Roswell Park Cancer Institute</keyword>
  <keyword>Department of Defense</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
